Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta

Trial Profile

Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Jul 2018 Planned number of patients changed from 3000 to 100.
    • 31 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 16 Jul 2018 Planned End Date changed from 21 Aug 2018 to 21 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top